V Micheli
Overview
Explore the profile of V Micheli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
88
Citations
327
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Viro-immunological evaluation in an immunocompromised patient with long-lasting SARS-CoV-2 infection
Mancon A, Rizzo A, Mileto D, Grosso S, Foschi A, Cutrera M, et al.
Emerg Microbes Infect
. 2022 Feb;
11(1):786-789.
PMID: 35209808
No abstract available.
2.
Mileto D, Micheli V, Fenizia C, Cutrera M, Gagliardi G, Mancon A, et al.
Emerg Microbes Infect
. 2022 Feb;
11(1):790-792.
PMID: 35196967
No abstract available.
3.
Mileto D, Fenizia C, Cutrera M, Gagliardi G, Gigantiello A, De Silvestri A, et al.
Emerg Microbes Infect
. 2021 Nov;
10(1):2235-2243.
PMID: 34749573
As the SARS-CoV-2 pandemic continues to rage worldwide, the emergence of numerous variants of concern (VOC) represents a challenge for the vaccinal protective efficacy and the reliability of commercially available...
4.
Minati L, Speranza G, Micheli V, Dalla Serra M, Clamer M
Dalton Trans
. 2020 Feb;
49(10):3333-3340.
PMID: 32101190
Integrating graphene as an inorganic nanostructure within a hydrogel matrix enables the creation of a unique hybrid composite combining the peculiar chemical and physical properties of graphene with the high...
5.
Minati L, Aguey-Zinsou K, Micheli V, Speranza G
Dalton Trans
. 2018 Sep;
47(41):14573-14579.
PMID: 30259035
We report a method to synthesize a palladium-functionalized porous graphene xerogel structure. A graphene xerogel nanocomposite with a three-dimensional microstructure was obtained by chemical reduction of an aqueous dispersion of...
6.
Rusconi S, Adorni F, Tau P, Borghi V, Pecorari M, Maserati R, et al.
J Clin Virol
. 2018 Jun;
105:112-117.
PMID: 29957545
Background: Dolutegravir (DTG) is a next-generation HIV integrase inhibitor (INI) with an increased genetic barrier to resistance with respect to raltegravir (RAL) or elvitegravir (EVG). Few data are available on...
7.
Milazzo L, Lai A, Calvi E, Ronzi P, Micheli V, Binda F, et al.
HIV Med
. 2016 Aug;
18(4):284-291.
PMID: 27477612
Objectives: Clinical trials of all-oral direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection reported high response rates in HCV/HIV coinfection, similar to those obtained in HCV monoinfection. We...
8.
Di Maio V, Cento V, Di Paolo D, Aragri M, De Leonardis F, Tontodonati M, et al.
J Antimicrob Chemother
. 2015 Dec;
71(3):739-50.
PMID: 26679249
Objectives: This study aims to evaluate the reliability and clinical utility of NS3 sequencing in hepatitis C virus (HCV) 1-infected patients who were candidates to start a PI-containing regimen. Methods:...
9.
Svicher V, Alteri C, Montano M, Nori A, DArrigo R, Andreoni M, et al.
Infection
. 2013 Oct;
42(1):61-71.
PMID: 24146352
Purpose: We have developed a sequencing assay for determining the usage of the genotypic HIV-1 co-receptor using peripheral blood mononuclear cell (PBMC) DNA in virologically suppressed HIV-1 infected patients. Our...
10.
Salpini R, Alteri C, Cento V, Pollicita M, Micheli V, Gubertini G, et al.
J Med Virol
. 2013 Apr;
85(6):996-1004.
PMID: 23588725
While the selection of complex HBV drug-resistance patterns on therapeutic failure can compromise the efficacy of anti-HBV therapies, recent data show that patients failing treatment without drug-resistance have a rate...